Oxford, WHO Launch 3 Bundibugyo Ebola Trials as DRC Outbreak Tops 2,300 Deaths
Updated
Updated · The Guardian · Aug 17
Oxford, WHO Launch 3 Bundibugyo Ebola Trials as DRC Outbreak Tops 2,300 Deaths
2 articles · Updated · The Guardian · Aug 17
Summary
Oxford University has begun human trials of a Bundibugyo Ebola vaccine, while the WHO is backing a DRC clinical trial of two antiviral therapies during a fast-worsening outbreak.
At least 4,900 cases and more than 2,300 deaths have been recorded, with health workers estimated to reach only 30% of cases before many patients die in the community.
The response is struggling because the outbreak involves the Bundibugyo species—without an established vaccine or antiviral—and may be spreading faster due to mutation, after months of misdiagnosis as malaria or typhoid.
Ituri province's conflict and militia activity have further hampered containment, while children account for a quarter of confirmed cases and nearly a third of deaths.
Routine care has also been disrupted, with maternal deaths in Ituri reportedly doubling, underscoring how weak international support and local instability are widening the crisis beyond Ebola itself.
With a 50% fatality rate and no approved vaccine, could the mutating Bundibugyo Ebola strain currently ravaging the DRC spark a global pandemic?
Are collapsing health systems and undetected mutations hiding the true global threat of the DRC's rapidly spreading Ebola crisis?
As militias block health workers in the DRC, will experimental mRNA vaccines arrive in time to stop the deadliest Ebola outbreak since 2016?
The 2026 Bundibugyo Ebola Outbreak in the DRC: Unprecedented Spread, Record Deaths, and the Global Race for a Vaccine
Overview
The 2026 Bundibugyo Ebola outbreak in the DRC began undetected in January near Mongbwalu, as early cases were misdiagnosed and diagnostic tests failed to identify the rare virus. This allowed the virus to spread silently for months, leading to a rapid escalation—reaching 2,000 cases in just two months, five times faster than previous outbreaks. High population mobility enabled cross-border transmission, while most new infections emerged outside known chains. The lack of early detection and absence of approved vaccines or treatments caused the fatality rate to soar. Ongoing violence, disrupted contact tracing, and funding shortfalls further overwhelmed frontline health workers, deepening the crisis.